SCHEMBL4329501

SCHEMBL4329501

N[C@@H]1CCN(c2ccc(F)cc2)C1=O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FPR2 P25090 1/20 0.45
MAPT P10636 5/20 0.43
TDP1 Q9NUW8 3/20 0.43
ALDH1A1 P00352 3/20 0.43
TSHR P16473 2/20 0.43
HTT P42858 2/20 0.43
LMNA P02545 1/20 0.43
MAPK1 P28482 1/20 0.43
GFER P55789 1/20 0.43
ALOX15 P16050 1/20 0.43
ROCK2 O75116 1/20 0.42
RAB9A P51151 1/20 0.41
CYP3A4 P08684 1/20 0.41
APEX1 P27695 1/20 0.41
LIPE Q05469 3/20 0.40
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
RECQL P46063 1/20 0.39
HSP90AA1 P07900 1/20 0.39
TP53 P04637 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14275589 1.00 FPR2 (0.45) FPR2MAPTTDP1ALDH1A1TSHR
SCHEMBL14635821 1.00 FPR2 (0.45) FPR2MAPTTDP1ALDH1A1TSHR
SCHEMBL28830882 0.88 TSHR (0.43) FPR2MAPTTDP1ALDH1A1TSHR
SCHEMBL5638931 0.88 TSHR (0.43) FPR2MAPTTDP1ALDH1A1TSHR
Hydrochloric Acid SCHEMBL5570296 0.83 NPC1 (0.55) RAB9ALIPE
Hydrochloric Acid SCHEMBL5570291 0.83 NPC1 (0.55) RAB9ALIPE
SCHEMBL14275582 0.82 HDAC6 (0.46) MAPTTDP1TSHRALOX15CYP3A4
SCHEMBL18048600 0.82 ROCK2 (0.47) FPR2MAPTTDP1ALDH1A1TSHR
SCHEMBL4333242 0.82 HTT (0.47) MAPTTDP1ALDH1A1TSHRHTT
SCHEMBL14275584 0.82 HTT (0.47) MAPTTDP1ALDH1A1TSHRHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090054457-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS ELZEIN ELFATIH 2009-02-26 US disclosed
US-7452889-B2 Substituted heterocyclic compounds CV THERAPEUTICS, INC. (US) 2008-11-18 US disclosed
US-20080032993-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS ELZEIN ELFATIH 2008-02-07 US disclosed
US-7262198-B2 Substituted heterocyclic compounds CV THERAPEUTICS, INC. (US) 2007-08-28 US disclosed
EP-1723129-A1 1-AKAN-2-OL SUBSTITUTED PIPERAZINE AND PIPERIDINE COMPOUNDS CV THERAPEUTICS, INC. (US) 2006-11-22 EP disclosed
US-20060229317-A1 Substituted heterocyclic compounds ELZEIN ELFATIH 2006-10-12 US disclosed
US-7115610-B2 Substituted heterocyclic compounds CV THERAPEUTICS, INC. (US) 2006-10-03 US disclosed
US-20050197346-A1 Substituted heterocyclic compounds CV THERAPEUTICS, INC. 2005-09-08 US disclosed
WO-2005061470-A1 1-AKAN-2-OL SUBSTITUTED PIPERAZINE AND PIPERIDINE COMPOUNDS CV THERAPEUTICS, INC. (US) 2005-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060229317-A1 Substituted heterocyclic compounds KCNH1, SDHA, COQ8A FPR2 4409/4885MAPT 4852/4885TDP1 3458/4885
US-20080032993-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS KCNH1, SDHA, COQ8A FPR2 4409/4885MAPT 4852/4885TDP1 3458/4885
US-20090054457-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS KCNH1, SDHA, COQ8A FPR2 4409/4885MAPT 4852/4885TDP1 3458/4885
US-20050197346-A1 Substituted heterocyclic compounds KCNH1, SDHA, COQ8A FPR2 4409/4885MAPT 4852/4885TDP1 3458/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.